An Open-label Study in Healthy Male Subjects to Investigate the Metabolism and Excretion Pathways of GLPG3667 Following a Single Oral Dose of [14C]-GLPG3667 and to Determine the Absolute Bioavailability Relative to an Intravenous [14C]-GLPG3667 Microtracer
Latest Information Update: 05 Jul 2022
At a glance
- Drugs GLPG 3667 (Primary) ; GLPG 3667
- Indications Inflammation; Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Galapagos NV
- 29 Jun 2022 Status changed from recruiting to completed.
- 27 Apr 2022 Status changed from not yet recruiting to recruiting.
- 13 Apr 2022 Status changed from planning to not yet recruiting.